Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator

Growth Hormone and IGF Research

Volumn 16, Issue 4, 2006, Pages 224-239

  Juncker Jensen, A ^a   Lykkesfeldt, A E ^a   Worm, J ^a   Ralfkiaer U ^a   Espelund, U ^b   Jepsen, J S ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antiestrogen resistance; Breast cancer; ICI 182,780 (Faslodex Fulvestrant); Insulin like growth factor binding protein 2; MCF 7; RU 58,668; Tamoxifen

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; ANTIESTROGEN; ANTISENSE OLIGONUCLEOTIDE; BIOCHEMICAL MARKER; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MESSENGER RNA; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG TARGETING; EXPERIMENTAL MODEL; GENE OVEREXPRESSION; GROWTH REGULATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; POLYUNSATURATED ALKAMIDES; RECEPTOR, IGF TYPE 1; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 33748080758     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2006.06.005     Document Type: Article

References (64)

1. Osborne C.K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 26 (1998) 1609-1618
2. Van de Velde P., Nique F., Bouchoux F., et al. RU 58,668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J. Steroid Biochem. Mol. Biol. 48 (1994) 187-196
3. Van de Velde P., Nique F., Bremaud J., Hameau M.C., Philibert D., and Teutsch G. Exploration of the therapeutic potential of the antiestrogen RU 58668 in breast cancer treatment. Ann. N. Y. Acad. Sci. 761 (1995) 164-175
4. Ali S., and Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2 (2002) 101-112
5. Katzenellenbogen B.S., Montano M.M., Ekena K., Herman M.E., McInerney E.M., and McGuire W.L. Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res. Treat. 44 (1997) 23-38
6. Briand P., and Lykkesfeldt A.E. Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res. 44 (1984) 1114-1119
7. Lykkesfeldt A.E., Madsen M.W., and Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 54 (1994) 1587-1595
8. Madsen M.W., Reiter B.E., Larsen S.S., Briand P., and Lykkesfeldt A.E. Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res. 57 (1997) 585-589
9. Lykkesfeldt A.E., Larsen S.S., and Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int. J. Cancer 16 (1995) 529-534
10. Fog C.K., Christensen I.J., and Lykkesfeldt A.E. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668. Breast Cancer Res. Treat. 91 (2005) 133-144
11. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 (1998) 1393-1396
12. Peyrat J.P., Bonneterre J., Hecquet B., et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur. J. Cancer 29A (1993) 492-497
13. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 (1998) 563-566
14. Wolk A., Mantzoros C.S., Andersson S.O., et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. 90 (1998) 911-915
15. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., and Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst. 91 (1999) 151-156
16. Ma J., Pollak M.N., Giovannucci E., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 91 (1999) 620-625
17. Augustin L.S., Dal M.L., Franceschi S., et al. Association between components of the insulin-like growth factor system and endometrial cancer risk. Oncology 67 (2004) 54-59
18. Kaaks R., Toniolo P., Akhmedkhanov A., et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J. Natl. Cancer Inst. 92 (2000) 1592-1600
19. Lee D.Y., Kim S.J., and Lee Y.C. Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J. Korean Med. Sci. 14 (1999) 401-404
20. el Atiq F., Garrouste F., Remacle-Bonnet M., Sastre B., and Pommier G. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int. J. Cancer 57 (1994) 491-497
21. Baron-Hay S., Boyle F., Ferrier A., and Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin. Cancer Res. 10 (2004) 1796-1806
22. Flyvbjerg A., Mogensen O., Mogensen B., and Nielsen O.S. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J. Clin. Endocrinol. Metab. 82 (1997) 2308-2313
23. Ho P.J., and Baxter R.C. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin. Endocrinol. (Oxf.) 46 (1997) 333-342
24. Shariat S.F., Lamb D.J., Kattan M.W., et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J. Clin. Oncol. 20 (2002) 833-841
25. Barrios V., Buno M., Pozo J., Munoz M.T., and Argente J. Insulin-like growth factor-binding protein-2 levels in pediatric patients with growth hormone deficiency, eating disorders and acute lymphoblastic leukemia. Horm. Res. 53 (2000) 221-227
26. Muller H.L., Oh Y., Lehrnbecher T., Blum W.F., and Rosenfeld R.G. Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J. Clin. Endocrinol. Metab. 79 (1994) 428-434
27. Gronbaek H., Flyvbjerg A., Mellemkjaer L., et al. Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 1759-1764
28. Kaaks R., Lundin E., Rinaldi S., et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13 (2002) 307-316
29. Keinan-Boker L., Bueno De Mesquita H.B., Kaaks R., et al. Circulating levels of insulin-like growth factor I, its binding proteins -1, -2, -3, C-peptide and risk of postmenopausal breast cancer. Int. J. Cancer 106 (2003) 90-95
30. Krajcik R.A., Borofsky N.D., Massardo S., and Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol. Biomarkers 11 (2002) 1566-1573
31. Busund L.T., Richardsen E., Busund R., et al. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J. Clin. Pathol. 58 (2005) 361-366
32. Burger A.M., Leyland-Jones B., Banerjee K., Spyropoulos D.D., and Seth A.K. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur. J. Cancer 41 (2005) 1515-1527
33. Diehl D., Hoeflich A., Wolf E., and Lahm H. Insulin-like growth factor (IGF)-binding protein-4 inhibits colony formation of colorectal cancer cells by IGF-independent mechanisms. Cancer Res. 64 (2004) 1600-1603
34. Gregory C.W., Kim D., Ye P., et al. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology 140 (1999) 2372-2381
35. Hao X., Sun B., Hu L., et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 100 (2004) 1110-1122
36. Miyake H., Nelson C., Rennie P.S., and Gleave M.E. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141 (2000) 2257-2265
37. Perks C.M., Bowen S., Gill Z.P., Newcomb P.V., and Holly J.M. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J. Cell Biochem. 75 (1999) 652-664
38. Bach L.A. IGFBP-6 five years on; not so 'forgotten'?. Growth Horm. IGF Res. 15 (2005) 185-192
39. Frogne T., Jepsen J.S., Larsen S.S., Fog C.K., Brockdorff B.L., and Lykkesfeldt A.E. Antiestrogen-resistant human breast cancer cells require activated Protein Kinase B/Akt for growth. Endocr. Relat. Cancer 12 (2005) 599-614
40. McCaig C., Perks C.M., and Holly J.M. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J. Cell Sci. 115 (2002) 4293-4303
41. Schutt B.S., Langkamp M., Rauschnabel U., Ranke M.B., and Elmlinger M.W. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J. Mol. Endocrinol. 32 (2004) 859-868
42. Pereira J.J., Meyer T., Docherty S.E., et al. Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res. 64 (2004) 977-984
43. Kiyama S., Morrison K., Zellweger T., et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res. 63 (2003) 3575-3584
44. Chatterjee S., Park E.S., and Soloff M.S. Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int. J. Urol. 11 (2004) 876-884
45. Bubendorf L., Kolmer M., Kononen J., et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J. Natl. Cancer Inst. 91 (1999) 1758-1764
46. Lundholt B.K., Briand P., and Lykkesfeldt A.E. Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res. Treat. 67 (2001) 199-214
47. Jepsen J.S., Pfundheller H.M., and Lykkesfeldt A.E. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides 14 2 (2004) 147-156
48. Krassas G.E., Papadopoulou P., Koliakos G., Konstantinidis T., and Kalothetou K. Growth hormone, insulin growth factor-1, and IGF binding protein-3 axis relationship with bone mineral density among healthy men. Arch. Androl. 49 (2003) 191-199
49. Nicholson R.I., Hutcheson I.R., Harper M.E., et al. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann. N. Y. Acad. Sci. 963 (2002) 104-115
50. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., and Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 30 276 (2001) 9817-9824
51. Gee J.M., Harper M.E., Hutchinson I.R., et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144 (2003) 5105-5117
52. Maxwell P., and van den Berg H.W. Changes in the secretion of insulin-like growth factor binding proteins -2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines. Cancer Lett. 139 (1999) 121-127
53. van den Berg H.W., Lynch M., Martin J., Nelson J., Dickson G.R., and Crockard A.D. Characterisation of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and ability of the resistant phenotype. Br. J. Cancer 59 (1989) 522-526
54. Chan T.W., Pollak M., and Huynh H. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clin. Cancer Res. 7 (2001) 2545-2554
55. Clemmons D.R., Camacho-Hubner C., Coronado E., and Osborne C.K. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology 127 (1990) 2679-2686
56. Milewicz T., Gregoraszczuk E.L., Sztefko K., Augustowska K., Krzysiek J., and Rys J. Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486). Growth Horm. IGF Res. 15 (2005) 140-147
57. Kim I., Manni A., Lynch J., and Hammond J.M. Identification and regulation of insulin-like growth factor binding proteins produced by hormone-dependent and -independent human breast cancer cell lines. Mol. Cell. Endocrinol. 78 (1991) 71-78
58. Dubois V., Couissi D., Schonne E., Remacle C., and Trouet A. Intracellular levels and secretion of insulin-like-growth-factor-binding proteins in MCF-7/6, MCF-7/AZ and MDA-MB-231 breast cancer cells. Differential modulation by estrogens in serum-free medium. Eur. J. Biochem. 232 (1995) 47-53
59. Pekonen F., Nyman T., Ilvesmaki V., and Partanen S. Insulin-like growth factor binding proteins in human breast cancer tissue. Cancer Res. 52 (1992) 5204-5207
60. Yee D., Favoni R.E., Lippman M.E., and Powell D.R. Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res. Treat. 18 (1991) 3-10
61. Sheikh M.S., Shao Z.M., Hussain A., et al. Regulation of insulin-like growth factor-binding-protein-1, 2, 3, 4, 5, and 6: synthesis, secretion, and gene expression in estrogen receptor-negative human breast carcinoma cells. J. Cell. Physiol. 155 (1993) 556-567
62. Dong F., Wu H.B., Hong J., and Rechler M.M. Insulin-like growth factor binding protein-2 mediates the inhibition of DNA synthesis by transforming growth factor-beta in mink lung epithelial cells. J. Cell. Physiol. 190 (2002) 63-73
63. Besnard V., Corroyer S., Trugnan G., et al. Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells. Biochim. Biophys. Acta 1538 (2001) 47-58
64. Wood T.L., Rogler L.E., Czick M.E., Schuller A.G., and Pintar J.E. Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene. Mol. Endocrinol. 14 (2000) 1472-1482